Intercept Pharmaceuticals, Inc. (ICPT)
-NasdaqGM | Prev Close: | 34.47 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 48.00 |
|---|
| Beta: | 0.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 17.96 - 42.67 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 34,600 |
|---|
| Market Cap: | 579.27M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -5.53 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INTERCEPT PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- InPlay: Intercept Pharma reports positive initial results from ongoing Phase 2a Trial in chronic bile acid diarrheaBriefing.com(Mon, May 20)
- Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid DiarrheaPR Newswire(Mon, May 20)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 17)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters toEDGAR Online(Mon, May 13)
- Top Life Science Investors Of 2013at Forbes(Thu, May 9)
- Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASLGlobeNewswire(Tue, Apr 30)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD DisclosurEDGAR Online(Tue, Apr 30)
- Intercept Pharmaceuticals to Present at Upcoming Healthcare ConferencesGlobeNewswire(Thu, Apr 25)
- Why Intercept Pharmaceuticals Is Poised to Pull Backat Motley Fool(Wed, Apr 24)
- Intercept Pharmaceuticals: The Risks That No One Is Talking Aboutat Seeking Alpha(Fri, Apr 19)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andEDGAR Online(Mon, Apr 15)
- Intercept Pharmaceuticals Announces Upcoming EASL PresentationGlobeNewswire(Mon, Apr 8)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 276.80 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.03 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.
View More 
0.34%